<DOC>
<DOCNO>EP-0641759</DOCNO> 
<TEXT>
<INVENTION-TITLE>
  Use of aromatic carboxylic derivatives for the preparation of drugs
</INVENTION-TITLE>
<CLASSIFICATIONS>C07C6976	A61K837	A61P1710	C07C69618	C07C6900	A61K910	A61P1700	A61Q1900	A61K819	A61Q1902	C07C6366	C07C69734	A61K858	A61K910	C07C5972	A61K31192	C07C5700	C07C5730	A61K31325	A61Q1900	C07C6300	C07C6994	A61K830	A61K3140	A61K8368	A61K3121	C07C6900	C07C5750	A61P1702	A61K867	A61K3140	A61K811	A61K834	A61K31325	A61P1716	C07C6364	A61K31216	A61Q1902	C07C6528	A61K819	A61P1700	A61K912	A61K31185	A61K908	C07C6500	A61K836	A61K841	C07C6538	A61K908	A61K31215	A61K804	C07C5900	A61K912	A61K906	A61K906	A61K3119	A61K804	A61K811	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07C	A61K	A61P	C07C	C07C	A61K	A61P	A61Q	A61K	A61Q	C07C	C07C	A61K	A61K	C07C	A61K	C07C	C07C	A61K	A61Q	C07C	C07C	A61K	A61K	A61K	A61K	C07C	C07C	A61P	A61K	A61K	A61K	A61K	A61K	A61P	C07C	A61K	A61Q	C07C	A61K	A61P	A61K	A61K	A61K	C07C	A61K	A61K	C07C	A61K	A61K	A61K	C07C	A61K	A61K	A61K	A61K	A61K	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07C69	A61K8	A61P17	C07C69	C07C69	A61K9	A61P17	A61Q19	A61K8	A61Q19	C07C63	C07C69	A61K8	A61K9	C07C59	A61K31	C07C57	C07C57	A61K31	A61Q19	C07C63	C07C69	A61K8	A61K31	A61K8	A61K31	C07C69	C07C57	A61P17	A61K8	A61K31	A61K8	A61K8	A61K31	A61P17	C07C63	A61K31	A61Q19	C07C65	A61K8	A61P17	A61K9	A61K31	A61K9	C07C65	A61K8	A61K8	C07C65	A61K9	A61K31	A61K8	C07C59	A61K9	A61K9	A61K9	A61K31	A61K8	A61K8	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The compounds of the formula 
<
IMAGE
>
  wherein R
<
1
>
 is a radical of the formulae 
<
IMAGE
>
 and R
<
2
>
-R
<
10
>
 have the meaning mentioned in the description, can be used as medicaments, particularly for dermatological and oncological indications.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
HOFFMANN LA ROCHE
</APPLICANT-NAME>
<APPLICANT-NAME>
F. HOFFMANN-LA ROCHE AG
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
KLAUS MICHAEL
</INVENTOR-NAME>
<INVENTOR-NAME>
MOHR PETER
</INVENTOR-NAME>
<INVENTOR-NAME>
KLAUS, MICHAEL
</INVENTOR-NAME>
<INVENTOR-NAME>
MOHR, PETER
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
The use of compounds of the formula


wherein

R
1
signifies a residue of the formula

R
2
signifies C
2-8
-alkanoyl, C
2-8
-alkyl, C
2-8
-alkenyl,
C
2-8
-alkynyl or -OCH
2
R
3
;
R
3
signifies hydrogen or C
1-6
-alkyl, C
2-6
-alkenyl or C
2-6
-alkynyl;
R
4
 to R
9
each independently signify hydrogen or C
1-5
-alkyl; or
R
8
 and R
9
together signify (CR
a
R
b
)
n
, R
a
 and R
b
 (sic) signify hydrogen
or C
1-5
-alkyl, n signifies 1, 2 or 3 and R
4
 to R
7
 signify the same
as above; or
R
8
 and R
9
together signify (CR
a
R
b
)
n
 and R
4
 and R
6
 together
signify methylene or ethylene, which can be substituted by

hydroxy, and R
a
,R
b
, R
5
, R
7
 and n signify the same as above;
R
10
signifies carboxyl, C
1-6
-alkoxycarbonyl or mono- or di-(C
1-6
-alkyl)carbamoyl
and the dotted bond in formula (a) is optional;
 
and pharmaceutically acceptable salts of carboxylic acids of formula I in the

production of pharmaceutical preparations for the therapy and prophylaxis of
light- and age-damaged skin and for the promotion of wound healing
The use according to claim 1 of compounds of formula I in
which R
1
 is a residue (a).
The use according to claim 1 of compounds of formula I in
which R
1
 is a residue (b).
The use according to claim 1-3 of compounds of formula I in
which R
2
 is C
2-8
-alkyl or -OCH
2
R
3
 and R
3
 is C
1-6
-alkyl.
The use according to claim 1-3 of compounds of formula I in
which R
2
 is C
2-8
-n-alkanoyl.
The use according to claim 1-3 of compounds of formula I in
which R
2
 is -OCH
2
R
3
 and R
3
 is C
2-6
-alkenyl or C
2-6
-alkynyl.
The use according to claim 1-6 of compounds of formula I in
which R
4
 to R
7
 each independently signify hydrogen or C
1-5
-alkyl and R
8
 and
R
9
 together signify (CR
a
R
b
)
n
.
The use according to claim 7 of compounds of formula I in
which R
8
 and R
9
 together signify methylene or ethylene.
The use according to claim 1 of the compounds

ethyl p-[(E)-2-(3-hexyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)vinyl]benzoate,
p-[(E)-2-(3-hexyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-vinyl]benzoic

acid,
(E)-4-[2-(3-pentyl-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)vinyl]benzoic

acid, 
(E)-4-[2-(3-butyl-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)vinyl]benzoic

acid,
methyl (2Z,4E,6E)-7-(3-hexyl-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-3-methyl-hepta-2,4,6-trienecarboxylate,
(all-E)-7-(3-hexyl-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-3-methyl-hepta-2,4,6-trienecarboxylic
acid,
(2E,4E,6E)-7-(3-pentyl-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-3-methyl-hepta-2,4,6-trienecarboxylic
acid,
(2Z,4E,6E)-7-(3-pentyl-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-3-methyl-hepta-2,4,6-trienecarboxylic
acid,
ethyl (E)-4-[2-(5,5,8,8-tetramethyl-3-propoxy-5,6,7,8-tetrahydro-naphthalen-2-yl)vinyl]benzoate,
(E)-4-[2-(5,5,8,8-tetramethyl-3-propoxy-5,6,7,8-tetrahydro-naphthalen-2-yl)vinyl]benzoic

acid,
(E)-4-[2-(5,5,8,8-tetramethyl-3-pentoxy-5,6,7,8-tetrahydro-naphthalen-2-yl)vinyl]benzoic

acid,
ethyl (2E,4E,6E)-3-methyl-7-(5,5,8,8-tetramethyl-3-propoxy-5,6,7,8-tetrahydro-naphthalen-2-yl)-hepta-2,4,6-trienecarboxylate,
(2E,4E,6E)-3-methyl-7-(5,5,8,8-tetramethyl-3-propoxy-5,6,7,8-tetrahydro-naphthalen-2-yl)-hepta-2,4,6-trienecarboxylic
acid,
(2Z,4E,6E)-3-methyl-7-(5,5,8,8-tetramethyl-3-propoxy-5,6,7,8-tetrahydro-naphthalen-2-yl)-hepta-2,4,6-trienecarboxylic
acid,
2E,4E,6E)-3-methyl-7-(5,5,8,8-tetramethyl-3-pentoxy-5,6,7,8-tetrahydro-naphthalen-2-yl)-hepta-2,4,6-trienecarboxylic
acid,
(2Z,4E,6E)-3-methyl-7-(5,5,8,8-tetramethyl-3-pentoxy-5,6,7,8-tetrahydro-naphthalen-2-yl)-hepta-2,4,6-trienecarboxylic
acid,
ethyl (E)-4-[2-(7,7-dimethyl-3-octyl-6,7,8,9-tetrahydro-5H-benzocyclo-hepten-2-yl)vinyl]benzoate,
(E)-4-[2-(7,7-dimethyl-3-octyl-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)vinyl)benzoic
acid,
rac-(E)-4-[2-(5,7,7-trmethyl-3-octyl-6,7,8,9-tetrahydro-5H-benzocyclo-hepten-2-yl)vinyl]benzoic

acid,
(E)-4-[2-(3-butyl-5,5-dimethyl-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)vinyl]benzoic

acid, 
(E)-4-[2-(3-hexyl-7,7-dimethyl-indan-2-yl)vinyl]benzoic acid,
(E)-4-[2-(3-hexyl-5,5-dimethyl-6,7,8,9-tetrahydro-5H-benzocyclo-hepten-2-yl)vinyl]benzoic

acid,
(E)-4-[2-(3-butyl-9,9-dimethyl-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)vinyl]benzoic

acid,
ethyl (E)-4-[2-[(5RS,9SR,10RS)-3-heptyloxy-10-hydroxy-5,9-dimethyl-6,7,8,9-tetrahydro-5,9-methano-5H-benzocyclohepten-2-yl]vinyl]
benzoate,
(E)-4-[2-[(5RS,9SR,10RS)-3-heptyloxy-10-hydroxy-5,9-dimethyl-6,7,8,9-tetrahydro-5,9-methano-5H-benzocyclohepten-2-yl]vinyl]
benzoic
acid,
ethyl (E)-4-[2-[(5RS,9SR,10RS)-3-butoxy-10-hydroxy-5,9-dimethyl-6,7,8,9-tetrahydro-5,9-methano-5H-benzocyclohepten-2-yl]vinyl]
benzoate,
(E)-4-[2-[(5RS,9SR,10RS)-3-butoxy-10-hydroxy-5,9-dimethyl-6,7,8,9-tetrahydro-5,9-methano-5H-benzocyclohepten-2-yl]vinyl]
benzoic
acid.
The use according to claim 1 of the compounds

ethyl (2E,4E)-3-methyl-7-(5,5,8,8-tetramethyl-3-pentyl-5,6,7,8-tetrahydronaphthalen-2-yl)-hepta-2,4-dien-6-ynoate,
(2E,4E)-3-methyl-7-(5,5,8,8-tetramethyl-3-pentyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-hepta-2,4-dien-6-ynoic
acid,
(2E,4E)-3-methyl-7-(5,5,8,8-tetramethyl-3-hexyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-hepta-2,4-dien-6-ynoic
acid,
ethyl (2E,4E,6E)-(5RS,9SR,10RS)-7-(3-butoxy-10-t-butyl dimethy-l
silyloxy-5,9-dimethyl-6,7,8,9-tetrahydro-5,9-methano-5H-benzocyclohepten-2-yl)-3-methyl-hepta-2,4,6-trienoate,
ethyl (2E,4E,6E)-(5RS,9SR,10RS)-7-(3-butoxy-10-hydroxy-5,9-dimethyl-6,7,8,9-tetrahydro-5,9-methano-5H-benzocyclohepten-2-yl)-3-methyl-hepta-2,4,6-trienoate,
(2E,4E,6E)-(5RS,9SR,10RS)-7-(3-butoxy-10-hydroxy-5,9-dimethyl-6,7,8,9-tetrahydro-5,9-methano-5H-benzocyclohepten-2-yl)-3-methyl-hepta-2,4,6-trienoic acid.
The use according to claim 1 of the compound 

(E)-4-[2-(3-hexanoyl-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)vinyl]benzoic

acid.
The use according to claim 1 of the compounds

2-bromo-3-propargyloxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalene,
2-formyl-3-pent-2-ynyloxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene,
ethyl (E)-4-[2-(3-pent-2-ynyloxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-vinyl]-benzoate,
(E)-4-[2-(3-pent-2-ynyloxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-vinyl]-benzoic

acid,
ethyl (2E,4E,6E)-3-methyl-7-(3-pent-2-ynyloxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-hepta-2,4,6-trienoate,
(2E,4E,6E)-3-methyl-7-(3-pent-2-ynyloxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-hepta-2,4,6-trienoic
acid,
(E)-4-[2-(3-allyloxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-vinyl]-benzoic

acid,
4-[(E)-2-((E)-3-but-2-enyloxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-vinyl]-benzoic

acid,
(2E,4E,6E)-7-(3-allyloxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-3-methyl-hepta-2,4,6-trienoic
acid,
(2E,4E,6E)-7-[(E)-3-but-2-enyloxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-3-methyl-hepta-2,4,6-trienoic
acid.
The use according to claim 1 of compounds of formula I in
which R
2
 is C
2-8
-alkyl or C
1-7
-alkoxy.
Compounds of formula I according to the definition in claim 1, in
which R
2
 is C
2-8
-n-alkanoyl.
Compounds of formula I according to the definition in claim 1, in
which R
2
 is -OCH
2
R
3
 and R
3
 is C
2-6
-alkenyl or C
2-6
-alkynyl.
</CLAIMS>
</TEXT>
</DOC>
